Literature DB >> 22695133

Pancreatic cancer in HIV-positive patients: a clinical case-control study.

Ernesto Zanet1, Massimiliano Berretta, Fabrizio Di Benedetto, Renato Talamini, Roberto Ballarin, Giuseppe Nunnari, Salvatore Berretta, Annalisa Ridolfo, Arben Lleshi, Antonio Zanghì, Alessandro Cappellani, Umberto Tirelli.   

Abstract

OBJECTIVES: Pancreatic cancer (PC) is the fourth and fifth most common cause of cancer-related death among men in United States and in Europe, respectively. No data are available for HIV-positive patients. The aim of this study was to investigate and to compare clinical presentation and outcome between HIV-positive and HIV-negative PC patients.
METHODS: From April 1988 to June 2010, the Italian Cooperative Group on AIDS and Tumors identified 16 cases of HIV-positive PC patients. Each HIV-positive patient from our institution was randomly matched (ratio 1:2) with HIV-negative patients (32 controls) based on sex and year of PC diagnosis. Differences in clinical presentation, treatment, and overall survival were assessed.
RESULTS: At multivariate analysis, HIV-positive patients compared with HIV-negative patients had a higher risk of an unfavorable performance status (PS ≥ 2) and a younger age (<50 years) at cancer diagnosis. At multivariate analysis, HIV-positive status and PS of 2 or greater were the only 2 features that significantly reduced PC patients' survival.
CONCLUSIONS: Our data show, for the first time, that HIV-positive PC patients, compared with HIV-negative patients, are younger at cancer diagnosis. Furthermore, they share a more unfavorable PS and a shorter survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695133     DOI: 10.1097/MPA.0b013e31824a0e40

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

Review 1.  The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review.

Authors:  Yoanna S Pumpalova; Leslie Segall; Richard Felli; Gauri Bhatkhande; Judith S Jacobson; Alfred I Neugut
Journal:  Semin Oncol       Date:  2021-09-22       Impact factor: 5.385

Review 2.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

3.  Pancreatic cancer: Current status and Challenges.

Authors:  Amanda R Muñoz; Divya Chakravarthy; Jingjing Gong; Glenn A Halff; Rita Ghosh; Addanki P Kumar
Journal:  Curr Pharmacol Rep       Date:  2017-10-11

Review 4.  Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review.

Authors:  Manuela Ceccarelli; Emmanuele Venanzi Rullo; Alessio Facciolà; Giordano Madeddu; Bruno Cacopardo; Rosaria Taibi; Francesco D'Aleo; Marilia Rita Pinzone; Isa Picerno; Michele di Rosa; Giuseppa Visalli; Fabrizio Condorelli; Giuseppe Nunnari; Giovanni Francesco Pellicanò
Journal:  Oncotarget       Date:  2018-03-30

5.  Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada.

Authors:  Maryam Darvishian; Zahid A Butt; Stanley Wong; Eric M Yoshida; Jaskaran Khinda; Michael Otterstatter; Amanda Yu; Mawuena Binka; Carmine Rossi; Geoff McKee; Margo Pearce; Maria Alvarez; Jason Wong; Darrel Cook; Troy Grennan; Jane Buxton; Mark Tyndall; Ryan Woods; Mel Krajden; Parveen Bhatti; Naveed Z Janjua
Journal:  Ther Adv Med Oncol       Date:  2021-02-11       Impact factor: 8.168

Review 6.  Chemotherapy-Induced Hepatotoxicity in HIV Patients.

Authors:  Silvia Bressan; Alessandra Pierantoni; Saman Sharifi; Sergio Facchini; Vincenzo Quagliarello; Massimiliano Berretta; Monica Montopoli
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

7.  In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4.

Authors:  Edwin A Higuita; Fabián A Jaimes; Maria T Rugeles; Carlos J Montoya
Journal:  AIDS Res Ther       Date:  2013-05-01       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.